Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer
Status:
Terminated
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, Phase 1b, dose escalation trial of Sym004 administered in
combination with 1 of 3 platinum-doublets in subjects with Stage IV Non-Small Cell Lung
Cancer (NSCLC).
The sponsor decided to discontinue the development of Sym004. Also the decision was made to
discontinue the development of Sym004 in NSCLC indication. The decision to discontinue Sym004
in NSCLC was not related to any safety or efficacy findings regarding Sym004. As a result of
the early discontinuation of the trial during the dose escalation part, the expansion cohort
will no longer be performed hence the pre-specified secondary endpoints are not analyzed and
were removed from the protocol based on protocol amendment 2 dated 31 March 2015.